MedTrace Logo

BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

NCT02876042 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2023-04-20

No results posted yet for this study

Summary

The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).

Conditions

Interventions

DEVICE

BAROSTIM NEO™ System

Implantation of the BAROSTIM NEO™ System

Sponsors & Collaborators

  • CVRx, Inc.

    lead INDUSTRY

Principal Investigators

  • Burkert Pieske, PhD · Universitätmedizin Berlin - Charité

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-23
Primary Completion
2024-07-31
Completion
2024-07-31
FDA Device
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02876042 on ClinicalTrials.gov